Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.

Background: Diabetic atherosclerosis and microangiopathy parallel diabetic nephropathy. The aim of our study was to evaluate the pattern of endothelial dysfunction in two vascular territories, the kidney and the brain, both affected by diabetic vasculopathic complications. The endothelial variability was evaluated in relation to advanced glycation end-products modified peptides. Methods: Seventy patients with type 2 diabetes mellitus and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C, intima-media thickness in the common carotid arteries, the pulsatility index, the resistance index in the internal carotid arteries and the middle cerebral arteries, the cerebrovascular reactivity through the breath-holding test. Results: The breath-holding index correlated with asymmetric dimethyl-arginine (R² = 0.151; p < 0.001), plasma advanced glycation end-products (R² = 0.173; p < 0.001), C-reactive protein (R² = 0.587; p < 0.001), duration of diabetes mellitus (R² = 0.146; p = 0.001), cystatin C (R² = 0.220; p < 0.001), estimated glomerular filtration rate (R² = 0.237; p = 0.001). Urine albumin: creatinine ratio correlated with urinary advanced glycation end-products (R² = 0.257; p < 0.001), but not with asymmetric dimethylarginine (R² = 0.029; p = 0.147). Conclusions: In type 2 diabetic patients endothelial dysfunction in the cerebral vessels appears to be dissociated from glomerular endothelial dysfunction in early diabetic nephropathy. Advanced glycation endproducts could impact both the cerebral vessels and the glomerular endothelium. [ABSTRACT FROM AUTHOR]